mogamulizumab
kyowa kirin
['mogamulizumab', 'lymsm']
#mogamulizumab in ccr4 atll #lymsm #elusm with chop-14. 1 yr pfs 36%, cr 64% and orr 91%. treatment works but durability is the issue. #asco23
An associate member @MoffittNews with interest in #lymsm. Tweets are not endorsements, and not medical advice.